Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception
- 22 June 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Pharmacology
- Vol. 13 (7), 685-694
- https://doi.org/10.1080/17512433.2020.1783247
Abstract
The use of progestin-only pills (POPs) is still relatively infrequent, mainly for their unpredictable effect on menstrual bleeding. A new POP consisting of 4 mg drospirenone (DRSP) for 24 days plus 4-day hormone-free interval has been developed to address this need. DRSP is a potent progestin analogue of spironolactone, with antiandrogenic and antimineralocorticoid properties. This is a narrative review of the available data on the pharmacotherapy of the new DRSP-only pill. The research includes aspects of pharmacokinetics/pharmacodynamics of the compound: the main focus is on the clinical effects of DRSP-only pill in terms of contraceptive efficacy, haemostatic effect, safety, tolerability and bleeding patterns. The DRSP-only pill presents a similar Pearl Index to that of common combined hormonal contraceptives: it is a POP with a better bleeding profile than traditional POPs (higher rates of scheduled bleedings and much lower rates of unscheduled intracyclic bleeding/spotting) which could increase its acceptability and the panorama of possible users. For these reasons, DRSP-only pill represents a real step forward in oral contraception with only progestins, even if the bleeding patterns during its use are still different to oestrogen-containing products (i.e. lower rates of scheduled bleedings and higher rate of amenorrhea).Keywords
This publication has 53 references indexed in Scilit:
- Pharmacology of different progestogens: the special case of drospirenoneClimacteric, 2005
- Progestogens in hormonal replacement therapy: new molecules, risks, and benefitsMenopause, 2002
- Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometriumFertility and Sterility, 2001
- The efficacy and tolerability of Valette®: a postmarketing surveillance studyThe European Journal of Contraception & Reproductive Health Care, 1999
- A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day: Collaborative Study Group on the Desogestrel-containing Progestogen-only PillThe European Journal of Contraception & Reproductive Health Care, 1998
- Effects of estrogens and progestogens on the renin-aldosterone system and blood pressureSteroids, 1996
- Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6-ethylene-15,16-methylene 17-spirolactonesJournal of Medicinal Chemistry, 1991
- Aldosterone Antagonists. 1. Synthesis and Activities of 6β,7β:15β,16β-Dimethylene Steroidal SpirolactonesJournal of Medicinal Chemistry, 1985
- Isolation and identification of spirorenone metabolites from the monkey (Macaca fascicularis)Steroids, 1982